EUVIMEDEUVIMED entdecken
Crossref

Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen

Yingfang He, Ruhua Tian, Dong Xu, Yanfei Wu, Sa Rina, Tengxiang Chen, Yihui Guan, Tianwu Xie, Tianlei Ying, Fang Xie, Junbin Han iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06941-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Yingfang He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron Emission Tomography Computed Tomography, Heterocyclic Compounds, Positron-Emission Tomography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Shanghai Pujiang Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Trophoblast glycoprotein, the so-called 5T4, is an oncofetal antigen expressed in many different cancers. However, no 5T4-specific radioligand is employed in the clinic for non-invasive diagnosis. Thus, the aim of the current study was to develop a PET radiotracer for imaging 5T4 expression in preclinical and clinical stages. METHODS: A VHH library was constructed by camel immunization. The specificity of the VHHs toward 5T4 antigen was screened through phage display biopanning and periplasmic extract enzyme-linked immunosorbent assay. 1,4,7-Triazacyclononane-1,4,7-triacetate acid (NOTA) derivative was conjugated to the selected VHH. After radiolabeling, microPET/CT and ex vivo biodistribution were conducted using BxPC-3 and MDA-MB-468 tumor-bearing mice. Cold VHH was co-injected with the tracer to challenge its binding in vivo. For the pilot clinical study, PET/CT images were acquired at 1 h after injection of tracer in patients with pathologically confirmed primary and metastatic tumors. RESULTS: A library with a capacity of 1.2 × 1012 colony-forming units was constructed after successful camel immunization. Nb1-40 with a median effect concentration of 0.43 nM was selected. After humanization, the resulting H006 maintained a high affinity towards 5T4. [68Ga]Ga-NOTA-H006 with the molar activities of 6.48-54.2 GBq/µmol was prepared with high radiochemical purity (> 98%). Using [68Ga]Ga-NOTA-H006, microPET/CT revealed a clear visualization of 5T4 expression in BxPC-3 tumor-bearing mice. Ex vivo biodistribution showed that the highest tumor-to-blood ratio (∼ 3-fold) and tumor-to-muscle ratio (∼ 5-fold) were achieved at 60 min post-injection. Co-injection of the cold H006 at a dose of 1.5 mg/kg significantly reduced the tumor uptake (p < 0.0001). In the pilot clinical study, [68Ga]Ga-NOTA-H006 demonstrated its capacity to map 5T4-positive lesions in humans and yielded a mean effective dose of 3.4 × 10- 2 mSv/MBq. CONCLUSIONS: [68Ga]Ga-NOTA-H006, which can visualize 5T4 expression in vivo, has been successfully developed. This opens up opportunities for non-invasively studying 5T4 expression through nuclear medicine. Further clinical investigations are warranted to explore its clinical value in disease progression and companion diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesPositron Emission Tomography Computed TomographyHeterocyclic CompoundsPositron-Emission TomographyHeterocyclic Compounds, 1-RingAnimalsHumansPilot ProjectsMiceFemaleTissue DistributionCell Line, Tumor

Stichwörter der Autor:innen

5T4Gallium-68Tracer developmentTrophoblast glycoprotein

Substanzen

Gallium Radioisotopes1,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic CompoundsHeterocyclic Compounds, 1-RingGallium-68

Autor:innen und Institutionen

  • Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.
  • Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China.
  • Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200233, China.
  • Huahe Pharmaceutical Co., Ltd, Shanghai, China.
  • MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan…

ORCID-Profile: Junbin Han

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission
  • Shanghai Pujiang Program

Zitieren

APA

He, Y., Tian, R., Xu, D., Wu, Y., Rina, S., Chen, T., Guan, Y., Xie, T., Ying, T., Xie, F., & Han, J. (2025). Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06941-1

Vancouver

He Y, Tian R, Xu D, Wu Y, Rina S, Chen T, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06941-1

BibTeX
@article{He2025,
  author = {He, Yingfang and Tian, Ruhua and Xu, Dong and Wu, Yanfei and Rina, Sa and Chen, Tengxiang and Guan, Yihui and Xie, Tianwu and Ying, Tianlei and Xie, Fang and Han, Junbin},
  title = {Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06941-1}
}
Kostenlos starten →